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Abstract 
 
 
Insulin has traditionally been the gold standard pharmacological treatment for 
gestational diabetes mellitus (GDM). Insulin requires multiple injections a day, can 
cause frequent hypoglycaemia, requires careful handling, and is generally more 
expensive compared to oral agents. Metformin has been increasingly popular in recent 
years. Based on the short-term data available, metformin appears to be safe and 
effective for the treatment of GDM but existing studies have all stressed the lack of 
longer-term offspring data. This article will analyse the evidence available on the 
longer-term outcomes in the offspring of women with GDM treated with metformin 
versus insulin. Pubmed, EMBASE, CENTRAL, and CNKI were searched for follow-
up studies of randomised controlled trials that compared metformin with insulin for 
the treatment of GDM. Existing follow-up studies did not find any significant increase 
in the risk of adverse effects in terms of growth and development in the offspring of 
GDM mothers managed with metformin versus insulin.  
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Longer-term Outcomes in Offspring of GDM mothers treated with metformin 
versus insulin 
 
 
1. Introduction 
 
The prevalence of gestational diabetes mellitus (GDM) has been increasing rapidly 
over the past two decades, with figures ranging widely between regions and 
countries.
1-3
 Insulin has traditionally been the gold standard treatment for GDM when 
diet and lifestyle modifications fail to provide satisfactory blood glucose control.
4-6
 
Figures vary according to the population studied, but around 15-30% of women with 
GDM require pharmacological therapy.
5,7
 Oral anti-hyperglycaemic agents such as 
metformin and glyburide have been increasingly popular in recent years as they are 
cheaper, do not require injections; and are easier to use and store when compared with 
insulin. The American Diabetes Association (ADA) considers glyburide to be inferior 
to both insulin and metformin, and emphasised that women must be counselled on the 
lack of long-term safety data for both metformin and glyburide.
8
 
 
In the offspring of women with GDM, neonatal complications include most 
commonly macrosomia and its complications, as well as prematurity, 
hyperinsulinaemia, hypoglycaemia, hypoxaemia, respiratory distress syndrome, 
asphyxia, polycythaemia, and postpartum hyperbilirubinaemia.
9-21
 Currently, the 
available evidence suggests that metformin use in women with GDM is relatively safe 
and effective when compared to insulin with respect to short-term maternal and 
offspring outcomes.
10,11,22-31
 However, data is sorely lacking regarding the longer-
term outcomes in offspring born to women with GDM treated with metformin versus 
insulin.  
 
While the longer-term outcomes of offspring with in-utero metformin exposure has 
mainly been studied in the offspring of women with GDM, metformin is also used in 
mothers with polycystic ovary disease (PCOS) and we will briefly summarise the 
evidence here. Mothers with PCOS are often prescribed metformin but again, there is 
very limited data regarding the longer-term effects of metformin use on the offspring 
in this cohort.
32,33
 A recent follow-up study that assessed the offspring of women with 
PCOS managed with metformin versus placebo reported higher BMI and increased 
prevalence of overweight/obesity in the children exposed to metformin in-utero when 
followed up at 4 years of age.
33
 A nonrandomized study reported no significant 
differences in birth length, birth weight, growth or motor-social development in the 
first 18 months of life when comparing gender-specific Centers for Disease Control 
and Prevention (CDC) infant data with 126 offspring born to PCOS mothers treated 
using metformin.
34
 A follow-up study of a randomised controlled trial (RCT) that 
randomised pregnant women with PCOS to metformin versus placebo reported that 
infants exposed to metformin in-utero were heavier than those in the placebo group at 
1 year of age (10.2 ± 1.2 kg vs 9.7 ± 1.1 kg, P = 0.003).
35
 
Here, we will analyse the emerging evidence on the longer-term outcomes of 
offspring born to women with GDM treated with metformin versus insulin (longer-
term outcomes are defined as outcomes beyond the first four weeks after birth). The 
effects of GDM on offspring growth and development will also be discussed. 
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1.1 The effects of GDM on offspring metabolic disease and future diabetes 
 
GDM has epigenetic effects at genes that are preferentially involved in diabetes and 
other metabolic diseases, as well as foetal growth and development (which may play a 
part in the association between GDM and macrosomia).
36,37
 Compared to the 
offspring of normoglycaemic mothers, offspring of mothers with GDM are more 
likely to be overweight or obese in childhood and adolescence, are more likely to 
have reduced insulin sensitivity and impaired pancreatic beta-cell function as adults, 
and are at greater risk of progressing to type 2 diabetes and metabolic syndrome.
38-44
  
 
A Finnish longitudinal cohort study found that, in comparison to adolescents born to 
non-diabetic mothers, adolescents born to mothers with GDM had a higher median 
BMI (20.8 vs 20.2 kg/m
2
), greater median waist circumference (73.3 vs 71.5 cm), 
higher fasting insulin levels (10.2 vs 9.3 milliunits/L), and were at increased risk of 
being overweight (18.8% vs 8.4%).
42
 Similarly, a study of Mexican-American 
mothers and their offspring found that, after adjusting for confounding variables, the 
group of children born to mothers with GDM had higher BMI measurements 
compared with the offspring of normoglycaemic mothers (the two groups were 
matched by age, BMI, and parity).
40
 A large German cohort study again showed a 
significant association between GDM and the risk of overweight, obesity, and 
abdominal adiposity in the offspring, after adjusting for potential confounders.
43
 
 
A recent study followed up 970 mothers from the Hyperglycemia and Adverse 
Pregnancy Outcome (HAPO)
45
 study and found that, at 7 years of age, offspring born 
to GDM mothers were more likely to be overweight or obese, have greater body-mass 
index (BMI) and higher blood pressure, have lower oral disposition indexes, have 
higher rates of abnormal glucose tolerance, and also demonstrated a trend toward 
reduced β-cell function, when compared to the offspring of mothers without GDM. 
Additionally, with each SD increase in maternal fasting, 1-h, and 2-h glucose levels 
on oral glucose tolerance tests (performed at 24-32 weeks of the index pregnancy), 
the risk of abnormal glucose tolerance in the offspring showed a corresponding 
increase. These associations were found to be independent of BMI before pregnancy, 
childhood obesity, or being born large for gestational age.
46
 
 
It has also been suggested that the exposure of a female foetus to maternal 
hyperglycaemia in-utero may increase the offspring's own risk of subsequently 
developing GDM in future pregnancies.
47,48
  
 
1.2 Neurodevelopment 
 
Ornoy et al. compared the neuropsychological function of 32 school age children born 
to GDM mothers and 57 children born to non-diabetic mothers matched by parental 
socioeconomic status, age, and birth order.
49
 The children born to GDM mothers were 
found to have lower gross and fine motor performance, lower cognitive scores, and a 
higher rate of attention deficit when compared to children born to non-GDM 
mothers.
49
 Another case control study (including 1835 singletons from the Quebec 
Longitudinal Study of Child Development and 998 twins from the Quebec Newborn 
Twin Study) concluded that GDM was associated with lower expressive language 
performance in offspring until middle childhood.
50
 The authors commented that genes 
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and maternal education both moderated the effect of gestational diabetes on 
expressive language during this period.
50
 
 
There is also some evidence to suggest that foetal postprandial brain responses may 
be slower in the offspring of mothers with GDM, and this finding raises the 
possibility that GDM may affect brain development and central nervous system 
insulin resistance in the foetus.
51
 
 
1.3 Blood pressure 
 
A systematic review and meta-analysis published in 2012 found that the offspring of 
mothers with GDM had higher systolic blood pressures compared to the offspring of 
non-diabetic mothers, but there was no difference in diastolic blood pressure between 
offspring of GDM and non-diabetic mothers.
52
 
 
1.4 Testicular size 
 
Tartarin et al. published a study in 2012 which found that, in human and mouse 
organotypic cultures in vitro, metformin reduced testosterone secretion and mRNA 
expression of the principal factors involved in steroid production.
53
 In vivo 
administration of metformin to pregnant mice resulted in decreased testicular size of 
the foetal and neonatal testes.
53
 While metformin treatment did not reduce the germ 
cell number, the number of Sertoli cells was slightly but significantly reduced in both 
foetal and neonatal periods.
53
  
 
2. Methods 
 
 
The aim of this article was to assess the longer-term outcomes in the offspring of 
women with GDM treated with metformin versus insulin. Literature searches were 
performed in (from inception to 27/05/2018): 
 Pubmed  
 EMBASE 
 CENTRAL 
 CNKI (China National Knowledge Infrastructure) 
 
We included all offspring follow-up studies of blinded and open-label RCTs 
comparing metformin versus insulin for the treatment of GDM.  
 
The search strategies for Pubmed, EMBASE, and CENTRAL are included in 
Appendices 1-3. The search strategy for CNKI was adapted from the search strategy 
for Pubmed. Two reviewers independently performed study selection. For any 
disagreements that could not be resolved by consensus, a third reviewer was asked to 
participate. 
 
3. Results 
 
Please see the search flow diagram in Figure 1. The search identified 4068 results 
from Pubmed, 343 results from Embase, and 387 results from CENTRAL (4798 
results in total). Seven offspring follow-up studies based on four RCTs were included 
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for review.
54-60
 The search identified 142 results from CNKI and no offspring follow-
up studies were identified. 
 
3.1 Body composition 
 
Rowan et al. published the Metformin in Gestational Diabetes: The Offspring Follow-
Up (MiG TOFU) study in 2011.
56
 This follow-up study assessed offspring at 2 years 
of age and included a smaller proportion of children of Polynesian ethnicity when 
compared with the original MiG RCT population (14 vs. 20%, P = 0.02). Baseline 
maternal characteristics and pregnancy outcomes did not differ between the follow-up 
groups. Children included in this follow-up study had a shorter crown-rump length at 
birth (33.0 vs. 33.5 cm, P = 0.005) and smaller triceps skinfolds (4.80 vs. 5.15 mm, P 
= 0.0002) and subscapular skin- folds (4.95 vs. 5.20 mm, P = 0.07) at birth when 
compared with the original MiG RCT population. Otherwise, the maternal and 
offspring baseline characteristics were not different between the follow-up group and 
the original MiG RCT population. When compared with the children of mothers 
treated with insulin, the offspring of metformin-treated mothers had slightly larger 
mid-upper arm circumferences (17.2 +/- 1.5 vs. 16.7 +/- 1.5 cm; P = 0.002) and 
subscapular (6.3 +/- 1.9 vs. 6.0 +/- 1.7 mm; P = 0.02) and biceps skinfolds (6.03 +/- 
1.9 vs. 5.6 +/- 1.7 mm; P =0.04).
56
 After adjusting for age, ethnicity, sex, and 
maternal glucose control during pregnancy, the P values were P = 0.005, P = 0.01, 
and P = 0.02 for upper-arm circumference, sub-scapular skinfold, and biceps skinfold 
respectively. Total fat mass and percentage body fat evaluated using bioimpedance (n 
= 221) and dual-energy x-ray absorptiometry (DEXA) (n =114) were not significantly 
different between groups. There were no significant differences between groups in 
terms of abdominal circumference, total fat mass, central fat measures, percentage 
body fat, or central-to-peripheral fat as measured by waist-to-hip ratio and DEXA-
calculated abdominal-to-thigh fat ratios.  
The MiG TOFU study followed up offspring from the Adelaide (n=109/181) and 
Auckland (n=99/396) subgroups at 7-9 years of age to assess body composition and 
metabolic outcomes using anthropometry, bioimpedance analysis (BIA), DEXA, 
magnetic resonance imaging (MRI), and fasting bloods.
60
 In the Adelaide subgroup, 
the population was predominantly European/Caucasian (89.7% and 84.3% in the 
metformin and insulin groups). Baseline maternal characteristics were generally 
similar between groups though women randomized to metformin versus insulin had 
higher glycaemia during treatment (p=0.002) and had more neonates with birth 
weight >90th percentile as assessed using customised birth weight charts (20.7%   vs 
5.9%; p=0.029). In comparison to the insulin group, offspring from the metformin 
group were younger by 5 months (p=0.02). At 7 years of age, no significant difference 
was found between groups in the Adelaide subgroup for all measures of body 
composition as well as fasting plasma glucose (nil other blood tests were performed in 
the Adelaide subgroup). The Auckland subgroup was ethnically heterogeneous, with 
55.6% and 38.9% of participants identifying as Caucasian/European in the metformin 
and insulin groups, respectively (ethnicity was not significantly different between 
groups, p=0.17). In the Auckland subgroup, mothers randomised to metformin had a 
trend towards higher body mass index (BMI) (p=0.08) and less weight gain during 
treatment (p=0.07). When assessed at 9 years of age, the metformin-exposed offspring 
were heavier (37.0±12.6kg vs 32.7±7.7kg; p=0.049), and larger in terms of waist 
circumference (69.1±12.2cm vs 64.2±8.4cm; p=0.04) and waist to height ratio 
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(0.51±0.08 vs 0.47±0.05; p=0.02). Metformin-exposed children had significantly 
larger mid-upper arm circumferences (23.0±4.3cm vs 21.2±2.9cm; p=0.02) as well as 
upper arm fat mass as measured by DEXA (1568±801 vs 1285±534g; p=0.047). Note 
that when the 6 children (3 each in the metformin and insulin groups) with signs of 
early puberty were excluded, body weight and DEXA arm fat mass were no longer 
significantly different between groups (p=0.07 for both measures). Percentage of 
body fat (as measured using DEXA and BIA) was similar between groups. Compared 
to the insulin group, children in the metformin group demonstrated a trend towards 
larger subcutaneous fat (3231±2412cm3 vs 2398±1566cm3; p=0.059) and visceral fat 
(941±629cm3 vs 722±365cm3; p=0.051) volumes as measured using abdominal MRI. 
Fasting glucose, triglyceride, insulin, insulin resistance, haemglobin, glycosylated 
hemoglobin (HbA1c), cholesterol, liver transaminases, leptin and adiponectin were 
similar between metformin and insulin groups. Adjusting for age, ethnicity and 
gender did not change findings for the Adelaide and Auckland subgroups. 
Tertti et al. compared the offspring of metformin-treated and insulin-treated GDM 
mothers at the age of 33 to 85 months.
58
 This follow-up study (designed to assess 
offspring testicular size) included 25 (42.4% of invited) and 27 (52.9% of invited) 
male offspring born to mothers with GDM treated with metformin or insulin 
respectively. There were no statistically significant differences between the two 
groups of boys in terms of waist-to-hip ratio (p=0.32), BMI (p=0.11), BMI z-score 
(p=0.16), height (p=0.95), or weight (p=0.61). The lack of female offspring is a major 
but expected limitation given that this follow-up study focused on testicular size. 
 
 
3.2 Growth and development 
 
Ijas et al. followed up offspring (at the ages of 6, 12, and 18 months) from their 
original RCT comparing metformin vs insulin in the treatment of GDM.
55
 Baseline 
maternal characteristics upon enrolment in the follow-up study were similar between 
groups for the Adelaide subgroup. While there was no significant difference between 
groups in terms of gestational age (p=0.355) and mean birth weight (p=0.119), 
neonates from the metformin group were significantly longer at birth (p=0.047). 
Information including weight and height measurements, and assessment of motor, 
social, and linguistic development was recorded during routine visits to child welfare 
clinics from 47/50 of offspring in the metformin group and 50/50 of offspring in the 
insulin group. This follow-up study found that offspring with intrauterine exposure to 
metformin were heavier at 12 months (10.47 vs 9.85 kg, 95% CI 0.04–1.20) and taller 
and heavier at 18 months (83.9 vs 82.2 cm, 95% CI 0.23–3.03, 12.05 vs 11.32 kg, 
95% CI 0.04–1.43) when compared to the offspring of GDM mothers treated with 
insulin. There was no statistically significant difference in body composition (as 
defined using the mean Ponderal Index) between the two groups of children 
(p=0.827). There was no statistically significant difference between groups in terms of 
motor development (assessed using measures including capability of standing and 
walking without support, normal pinch grip, and coordination of upper limbs) when 
the offspring were assessed at 18 months. Social, emotional, and language 
development was assessed by evaluating the response to spoken commands, and the 
ability to make understandable spoken words and reciprocal contact. Again, there was 
no statistically significant difference between groups in terms of social, emotional and 
language development. Ijas et al. concluded that in-utero exposure to metformin did 
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not appear to adversely affect early motor, linguistic, or social development. A 
limitation of this study was the small sample size, which did not allow detection of 
differences in infrequent or rare conditions (e.g. developmental delays) between the 
two groups of children. 
 
Tertti et al. followed up the 2-year-old children of GDM mothers treated with 
metformin vs insulin.
57
 Maternal and neonatal baseline characteristics were similar 
between groups. From the original RCT, 151 (74.4%) children participated in this 
follow-up study. Cognitive, language, and motor skills as well as neurological 
examination findings were evaluated using the Bayley Scales of Infant and Toddler 
Development (Bayley-III) and the Hammersmith Infant Neurological Examination. 
There was no statistically significant difference between the offspring of metformin- 
and insulin-treated mothers in terms of receptive communication (p=0.14), expressive 
communication (p=0.75), fine motor performance (p=0.10), gross motor performance 
(p=0.13), global scores of the Hammersmith Infant Neurological Examination 
(p=0.14), or results when tested using the Bayley-III scales (p=0.12). None of the 
children followed up had a clinically significant developmental problem that required 
further assessment by a psychologist or paediatric neurologist. Tertti et al. reported 
weaker language performance in the offspring of GDM mothers (treated with both 
metformin and insulin) when compared with age-adjusted Finnish normative data.
57
 
 
 
Wouldes et al. followed up (at 2 years of age) 211 children from New Zealand and 
Australia out of the 577 eligible offspring that were born to mothers from the MiG 
trial.
59
 At follow-up, no significant differences were found between groups for most 
family environment and socio-economic status measures. While the New Zealand 
cohort birth length in the insulin group was longer than that in the metformin group 
(p=0.03), perinatal outcomes were similar between the offspring from the metformin 
and insulin groups. Neurodevelopment was evaluated with the Bayley Scales of Infant 
Development V.2 mental development index (MDI) and psychomotor development 
index (PDI). A paediatrician performed a structured physical examination on the 95 
children from New Zealand but a formal physical examination was performed on only 
10 of the Australian children. At follow-up, no statistically significant differences 
were detected between groups in terms of global cognitive and motor development. 
However, Wouldes et al. reported significantly lower scores for both cognitive and 
motor development in the offspring from New Zealand compared with Australian 
offspring. 
Wouldes et al. reported that children with a birth weight >4000 g were found to be at 
greater risk of poorer cognitive development.
59
 Additionally, children with two or 
more episodes of neonatal hypoglycaemia (blood glucose <2.6 mmol/L) and those 
born to mothers with higher glucose levels were more likely to have poorer motor 
development regardless of whether the mothers were treated with metformin or 
insulin. Wouldes et al. concluded that, at the age of 2 years, the neurodevelopment of 
children born to women with GDM did not differ according to treatment with 
metformin or insulin. However, this study was limited by the large lost to follow-up 
rate.  
3.3 Blood pressure 
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Battin et al. published a study in 2015 which followed up offspring of the MiG
61
 trial 
at 2 years of age to assess systolic and diastolic blood pressure.
54
 Blood pressure 
measurements were obtained in 170 children (median age of 29 months corrected 
gestational age). No significant differences were found in the distribution of 
metformin vs insulin treatment by ethnicity. There was no evidence of any 
statistically significant difference in blood pressure at 2 years of age when comparing 
offspring from the metformin and insulin treatment groups, with height and weight 
being the only two factors associated with the blood pressure measurements.
54
 This 
study was quite limited given that blood pressure measurements were obtained from 
just less than 30 percent of the 577 children potentially available from the original 
MiG RCT. Further follow-up down the track would be required as monitoring at 2 
years of age is probably too early to capture differences in blood pressure and/or 
cardiovascular health. 
3.4 Testicular size 
 
Tertti et al. compared testicular size (by a ruler, an orchidometer, and by 
ultrasonography) in the offspring of metformin-treated and insulin-treated GDM 
mothers at the age of 33 to 85 months.
58
 A total of 52 boys (42.4% of offspring from 
the metformin group and 52.9 % of offspring from the insulin group) were included, 
with 25 born to metformin-treated mothers and 27 born to insulin-treated mothers. 
The mean age of offspring did not differ significantly between groups (p = 0.88). 
There were no significant differences between the two groups of boys in terms of 
testicular size (p always ≥ 0.40). 
 
4. Discussion  
 
The MiG TOFU study found that the offspring of metformin-treated mothers had a 
slight but statistically significant increase in biceps skinfolds, mid-upper arm 
circumferences, and subscapular skin folds.
56
 Subsequently, Rowan et al. suggested 
that in-utero exposure to metformin resulted in a favourable increase in fat deposition 
at subcutaneous sites and likely less visceral fat in the offspring.
56
 The MiG TOFU 
study found no significant difference between groups for abdominal circumference 
and crude measures of central fat.
56
 While abdominal circumference has been 
suggested as a good surrogate measure of visceral fat in adults and children
62-64
, other 
studies have reported that waist circumference may in fact be more predictive of 
abdominal subcutaneous fat in children
65
. It has also been suggested that waist 
circumference in children may be more highly correlated with the accumulation of 
whole body fat rather than abdominal visceral fat.
5,66
 In the context of excessive 
nutritional intake in adults, healthy subcutaneous adipocytes grow and become 
dysfunctional.
56,67,68
 Excess fat then deposits in visceral adipocyte depots which 
release fatty acids and inflammatory adipocytokines that are associated with insulin 
resistance.
56,65,67-71
 Contrastingly, insulin-sensitive obesity is associated with a higher 
proportion of healthy subcutaneous adipocytes and smaller amounts of visceral 
fat.
56,65,67-71
 It is unclear whether the same pattern is seen in children. However, there 
is some evidence to suggest that, unlike in adults, subcutaneous adiposity instead of 
visceral adiposity may in fact be the strongest predictor of insulin resistance and 
hypertriglyceridemia in children.
72-75
 Therefore, the clinical significance of the 
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increase in fat deposition at subcutaneous sites at 2 years of age in the MiG TOFU 
study
56
 remains unclear. Rowan et al. subsequently made use of abdominal MRI when 
following up offspring at 7-9 years, and found a trend towards larger volumes of both 
subcutaneous fat (p=0.059) and visceral fat (p=0.051) in the metformin group 
compared to the insulin group among children from the Auckland subgroup.
60
 
Children in the metformin group were also significantly heavier though when the 
children with signs of early puberty were excluded, body weight was no longer 
significantly different between groups (p=0.07). While the increase in body weight 
may be a consequence of puberty, the literature also demonstrates a well-described 
positive relationship between weight/BMI and the onset and progression of puberty 
for both sexes.
76-78
 These findings need to be considered in the context of previous 
studies which found that metformin-exposed children of PCOS mothers were heavier 
than those born to PCOS mothers treated with placebo.
35,33 
Future studies could 
perhaps explore whether any increase in weight in children with metformin exposure 
in-utero may be associated with changes in metabolism (in particular any insulin-
mediated pathways). 
Wouldes et al. reported significantly lower scores for both cognitive and motor 
development in the offspring from New Zealand compared with Australian offspring. 
Subsequent analyses indicated that lower scores were predominantly associated with 
maternal ethnicity (Pacific or Indian) or lifestyle factors, and with higher scores being 
associated with Caucasian ethnicity.
59
  A greater proportion of offspring from the 
follow-up study were of European or white ethnicity when compared with the original 
MiG RCT population (metformin 68% vs 44%, p<0.001; insulin 58% vs 43%, 
p<0.005).
59
 A smaller proportion of offspring of Pacific or Polynesian ethnicity were 
included in this follow-up study at 2 years when compared with the original MiG 
RCT population (metformin 7% vs 22%, p<0.001; insulin 13% vs 21%, p<0.060). It 
was noted that a similar proportion of Pacific Island families were available for 
follow-up in the metformin and insulin groups. Similarly, in the Adelaide subgroup 
from the MiG TOFU follow-up study that assessed offspring at 7-9 years of age, 
participants were predominantly Caucasian (though the authors noted that adjusting 
for ethnicity did not change their findings).
60
 The results from these follow-up studies 
or subgroups may not be suitable for extrapolation to non-Caucasion populations. 
This highlights the importance of assessing ethnicity and lifestyle factors when 
examining offspring development. However, maternal ethnicity and socioeconomic 
measures were only reported by the follow-up studies of the MiG trial.
54,56,59
  
There was no evidence of any significant difference in neurodevelopmental outcome 
between the offspring of women with GDM treated with metformin versus 
insulin.
57,55,59,60
 Based on these findings, we believe that there is currently no strong 
indication for additional neurodevelopmental assessment in early childhood for the 
offspring of GDM mothers treated with metformin when compared to the offspring of 
GDM mothers treated with insulin. 
 
Tertti et al. reported weaker language performance in the offspring of GDM mothers 
when compared with age-adjusted Finnish normative data.
57
 Further assessment is 
required to determine if this difference in language performance persists later on in 
childhood and/or adulthood, and to determine if extensive and systematic testing of 
language performance may be necessary in the offspring of women with GDM. 
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Given that offspring data remains relatively limited, further high-quality follow-up 
studies are necessary to determine the presence and significance of any differences in 
long-term outcomes observed in children born to metformin- or insulin-treated 
mothers with GDM. Evidence is also lacking on whether any differences between 
groups in early childhood persist later in life, and how postnatal factors can mask or 
influence the effects of metformin exposure in-utero.  
 
5. Conclusions 
 
While it may be premature to draw final conclusions at this point in time, the existing 
follow-up studies are encouraging and do not show an increased risk of adverse 
effects in terms of growth and development in the children of GDM mothers treated 
with metformin versus insulin. These findings are reassuring for women with GDM 
treated with metformin, as well as their families and clinicians. In practice, clinicians 
should continue to ensure that all mothers with GDM considering metformin therapy 
are counselled regarding the relatively limited but nonetheless encouraging offspring 
data available. Ethnicity and lifestyle factors may influence offspring outcomes in a 
complex fashion and we believe that future studies would benefit from discussing 
ethnicity and lifestyle factors when reporting baseline characteristics and results.  
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